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Abstract 
 
Ligaments are prone to injury and degeneration in humans and animals, however the 
healing potential of ligament is poor and current treatment options ineffective. Stem cell-
based therapies hold potential for treatment of ligament injuries. This study aimed to 
characterise a ligament progenitor cell (LPC) population and to identify specific niche 
components which could promote the survival and function of LPCs. LPCs were isolated from 
canine cranial cruciate ligament and characterised for clonogenicity, multipotency and 
marker expression. The extracellular matrix (ECM) composition was characterised by the 
novel application of a metabolic labelling and mass spectrometry technique. LPCs 
demonstrated clonogenicity, multipotency and stem cell marker expression. A number of 
different collagens, glycoproteins and proteoglycans were identified in the LPC niche using 
proteomics. Metabolic labelling of cells demonstrated unique turnover profiles for distinct 
ECM protein groups, indicating the importance of certain niche components for LPC survival 
and function. The newly synthesised niche components identified in this study could be 
exploited to aid identification of LPCs and to promote their survival and function for potential 
ligament repair strategies. 
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Introduction 
 
Musculoskeletal soft tissues such as ligament are primarily composed of extracellular 
matrix (ECM) within which ligament cell populations reside. These tissues are prone to injury 
and degeneration, particularly the anterior cruciate ligament (ACL) 1, with an incidence of 
approximately 37 ACL ruptures per 100,000 people 2 and a greater incidence among athletes 
3. However, current treatment strategies for ACL repair are often ineffective and the healing 
potential of ACL is poor 4. ACL injury can cause a loss of knee joint stability leading to 
considerable morbidity and ultimately osteoarthritis 5-7. Ligament injury is also a common 
problem in comparative species such as dogs. Rupture of the cranial cruciate ligament (CCL), 
comparable to the human ACL, is the predominant cause of canine hind limb lameness 8. 
Study of the canine CCL is also important for its translation into humans as a model for ACL 
disease 9-10. Current treatment strategies for human ACL and canine CCL injuries have variable 
success rates 11-16, therefore a more effective therapeutic option for treatment of ACL and 
CCL injury is currently being sought. 
The identification of a population of cells within ACL which possess stem cell 
properties 17 holds therapeutic potential for ligament repair in humans and dogs. Ligament-
derived stem cells (LPCs) isolated from human ACL express stem cell and tenogenic markers 
18-20, form colonies 21 and differentiate into osteogenic, adipogenic and chondrogenic cell 
types 17-18. Human periodontal and rabbit medial collateral ligament LPCs have been used in 
tissue engineering strategies, and to treat human periodontal and rat medial collateral 
ligament injuries 22-24 with promising results, indicative of the potential of LPCs for treatment 
of ACL injuries.  
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1The stem cell niche is the environment in which stem cells reside and consists of a 
number of different cellular and molecular factors 25. One factor is the protein composition 
of the extracellular matrix (ECM) which has been shown to be integral for stem cell survival 
and function in a number of different cell populations. For example, the role of tenascin C 
in the neural stem cell niche 26-27, fibronectin in the haematopoietic stem cell niche 28-30 and 
fibromodulin in the tendon stem cell niche 31. The role of ECM proteins in stem cell 
regulation in these tissues, particularly tendon, is suggestive of the importance of the LPC 
niche in LPC regulation. There are a number of techniques that can be utilised to investigate 
the stem cell niche, one of which is mass-spectrometry based proteomics 32-33. Label-free 
mass spectrometry can be used for protein identification and quantification of ECM 
components in ligament and tendon 34-35. Label-based mass spectrometry methods can be 
used to measure protein dynamics 36-37. Proteomic analysis of a cell or tissue provides only 
a snapshot of that cell or tissue’s proteome at a single point in time. The proteome is 
constantly changing as proteins are synthesised and degraded reflecting the developmental, 
physiological and pathological status of the cell or tissue 36, 38. Therefore, the investigation 
of proteome dynamics is integral to fully understand the function and role of proteins within 
their niche. 
This study aimed to characterise LPCs isolated from canine CCL for clonogenicity, 
multipotency and marker expression, and to identify components of the LPC niche with 
potential to promote LPC survival and function. This was achieved using label-free mass 
spectrometry for protein identification and quantification, and dynamic SILAC for 
investigation of the rates of protein synthesis and turnover in the niche. Characterisation of 
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LPCs from canine CCL and proteomic determination of the LPC niche has not previously been 
reported, neither has the use of dynamic SILAC to characterise the niche of any cell 
population. We hypothesised that LPCs isolated from canine CCL would demonstrate the 
hallmark properties of stem cells and would generate a specific ECM niche, but and that this 
niche would be dynamic in order to meet the changing cellular demands of stem cell 
populations. 
 
 
Experimental Procedures 
 
Isolation of canine ligament cells 
CCLs were harvested from 9 disease-free canine cadaveric stifle joints (animals aged 
3-7 years) which were euthanased for purposes not related to this study and were clinical 
waste material donated to the University of Liverpool. Ethical approval for use of this material 
in this project was granted by the local ethics committee (VREC159 and RETH00000553). The 
tissue was dissected into small pieces and digested overnight at 37°C in 1 mg/ml collagenase 
II. The resulting cell suspension was strained and the cells were resuspended in complete 
DMEM (DMEM supplemented with 10% foetal calf serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 µg/ml amphotericin B). For LPC isolation the cells were seeded at 1200 
cells/cm2 onto plates previously coated with 20 µg/ml human fibronectin and the media 
(complete DMEM + 5 ng/ml FGF-2) replaced after 20 minutes 39-40. The cells were cultured at 
37°C, 5% CO2 and 5% O2 for 10-12 days until they formed colonies. The colonies were isolated 
using 0.05% trypsin and transferred to T25 culture flasks 39. All experiments were performed 
at passage 2-3. 
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Colony formation assay 
Ligament-derived cells from 9 dogs were seeded at 100 cells/cm2 in 6-well cell culture 
plates. After 7 days in culture the cells were fixed with 6% glutaraldehyde and stained with 
0.5% crystal violet solution 41. Colonies were imaged using a biomolecular imager (Typhoon 
FLA 7000; GE Healthcare, Illinois, USA), and analysed using ImageQuant software (GE 
Healthcare) for colony number and size. 
 
Tri-lineage differentiation assays 
Ligament-derived cell monolayers from 9 dogs were cultured for 21 days in osteogenic 
(complete DMEM containing 100 nM dexamethasone, 10 mM β-glycerophosphate and 50 mM 
ascorbic acid) 42 or adipogenic (complete DMEM containing 1 µM dexamethasone, 100 µM 
indomethacin, 10 µg/ml insulin and 500 µM IBMX) 17 induction media. Cell pellets (containing 
5x105 cells) were cultured for 21 days in chondrogenic (complete DMEM containing 100 nM 
dexamethasone, 25 µg/ml ascorbic acid, 10 ng/ml TGF-β3 and ITS+3 supplement) 43 induction 
media. All control cells were cultured in complete DMEM for 21 days. Subsequently cells were 
stained with alizarin red to assess osteogenic differentiation and Oil Red O to assess 
adipogenic differentiation as described in the PromoCell MSC application notes 
(http://www.promocell.com/downloads/application-notes/). Chondrogenic pellets were 
paraffin embedded and 4 µm sections taken, which were rehydrated and stained with 1% 
Alcian blue solution. Cell pellets were also digested in 10 U/ml papain solution for 3 hours at 
60°C before the total sulphated glycosaminoglycan (GAG) content was quantified. 
Dimethylmethylene dye was added to each sample and the absorbance read immediately at 
570 nm. The GAG content was calculated from a standard curve produced using chondroitin 
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sulphate standards 44. RNA was extracted from all assays to analyse lineage-specific gene 
expression. 
 
RNA extraction and qRT-PCR 
RNA was extracted from ligament-derived cells from 9 dogs using Trizol. cDNA was 
synthesised in a 25 µl reaction from 1-2 µg of total RNA. The conditions for cDNA synthesis 
were as follows: incubation at 5 minutes at 70°C, 60 minutes at 37°C and 5 minutes at 93°C 
with M-MLV reverse transcriptase and random-hexamer oligonucleotides 45-46. qRT-PCR was 
conducted using a GoTaq(R) qPCR Master Mix, and in a 25 µl reaction 10 ng of cDNA was 
amplified in an AB 7300 Real Time PCR System (Applied Biosystems, California, USA). After an 
initial denaturation for 10 minutes at 95°C, 40 PCR cycles were performed consisting of 15 
seconds at 95°C and 1 minute at 60°C 45-46. Relative gene expression was calculated according 
to the comparative Ct method 47. Canine specific primers (Table 1) were designed using Primer-
BLAST (NCBI) and the quality of each primer was tested using NetPrimer (Premier Biosoft). In 
addition, each primer was subjected to a BLAST (NCBI) search to ensure specificity. The best 
housekeeping gene was determined using the geNorm algorithm 48 and all primers were 
tested for efficiency; efficiencies between 90-110% were deemed to be acceptable. 
 
Table 1. Primer sequences for canine genes. 
Gene Forward Reverse 
GAPDH CTGGGGCTCACTTGAAAGG CAAACATGGGGGCATCAG 
CD90 TGTGCTCAGAGACAAACTGGT CAGCCAGTCACAGGGAGATG 
CD73 ATGGCTCCACTCAATCCTGC TCCCAGGTAATTGTGCCGTT 
8 
 
CD105 GACGCCGAGGTGACATACAT GCTCTGACAGCTCCCTTGAG 
CD44 ACCTTCCAACTGCATACCCG TCGTGGTCTTTGGTAATGGGG 
SCX GTCCAGCTACATCTCGCACC GTCCAGCTACATCTCGCACC 
MKX GCGACCCCGGAGTTCTTC CGCGGTCCTCAAAAAGCAC 
OCT-4 GAGGCTCTGCAGCTCAGTTT AGCCCAGAGTGGTGACAGAC 
TNMD CCCACTCTAATAGCAGTTTCAGA TCCTCACTTGCTTGTCTGGT 
RUNX2 GAACCCAGAAGGCACAGACA ACTTGGTGCAGAGTTCAGGG 
FABP4 ATCAGTGTAAACGGGGATGTG GACTTTTCTGTCATCCGCAGTA 
COL2A1 AGCTAAAGGATCTGCTGGCG CTTGTTCGCCTTTGAAGCCA 
 
 
 
13C metabolic labelling of ECM proteins for proteomic analysis 
Ligament-derived cells isolated from 3 dogs were plated at 6x104 cells/cm2 in complete 
DMEM (phenol red free) and incubated for 24 hours. Cells were then incubated in complete 
SILAC media (Sigma Aldrich, Missouri, USA) (SILAC media supplemented with 100 U/ml 
penicillin, 100 µg/ml streptomycin and 2 µg/ml amphotericin B, 0.2 mM ascorbate and 0.4 
mM β-aminopropionitrile) as well as 0.8 mM [12C]L-lysine 2HCl, 0.4 mM [12C]L-arginine HCl 
and 0.4 mM [12C]L-proline (ThermoFisher Scientific, Massachusetts, USA)) (unlabelled media) 
for 1 hour. The media was then exchanged for complete SILAC media supplemented with 0.8 
mM [13C]L-lysine 2HCl, 0.4 mM (ThermoFisher Scientific) [12C]L-arginine HCl and 0.4 mM 
[12C]L-proline (labelled media) for 4, 24 and 48 hours. After which the cells were removed 
using trypsin and the plates washed with PBS. 
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Extracellular matrix extraction  
Rapigest (Waters, Massachusetts, USA) solution (0.06% (w/v) solution in 25 mM 
NH4HCO3) was applied to each plate and incubated for 30 minutes at room temperature 
before incubation at 80C for 10 minutes 49. Protein extracts were reduced by the addition of 
10 µl of 60 mM DTT in 25 mM NH4HCO3 followed by sample incubation at 60C for 10 minutes. 
Alkylation was carried out by the addition of 10 µl of 180 mM iodoacetamide in 25 mM 
NH4HCO3 and the sample incubated at room temperature for 30 minutes in the dark. 10 µl of 
0.05 µg/µl trypsin was added to samples before incubation at 37C overnight. Digests were 
terminated by the addition of trifluoroacetic acid and incubated at 37C for 45 minutes, 
before centrifugation at 17,200 g for 30 minutes and transfer of the clarified digest to fresh 
low-bind tubes. 
 
Liquid chromatography- tandem mass spectrometry (LC-MS/MS) 
Samples (ECM extracts from cultured cells) were randomised and run on a 1 hour 
gradient with a 30 minute blank between samples to eliminate contamination. For instrument 
performance evaluation, E.coli digest standards spiked with RePLiCal 50 were included before 
and after the run. Data-dependent LC-MS/MS analyses were conducted on a QExactive 
quadrupole-Orbitrap mass spectrometer (ThermoFisher Scientific) 51-52 coupled to a Dionex 
Ultimate 3000 RSLC nano-liquid chromatograph (ThermoFisher Scientific). Further detail is 
given in Supporting Information. 
 
Proteomic data analysis 
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE 53 partner repository 
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(http://www.ebi.ac.uk/pride/archive/) with the dataset identifier PXD008602 and 
10.6019/PXD008602. Reviewer account details to access the data are username: 
reviewer46873@ebi.ac.uk; password: j6QM8ynz. 
For protein identification and label-free quantification raw data files were imported 
into PEAKS v.8 (Bioinformatics Solutions Inc, Waterloo, Canada) 54 and de novo and database 
PEAKS searches were carried out using the UniProtKB canine protein database (EMBL-EBI, 
Hinxton, UK) 55. Protein identifications and gene ontology were analysed using the UniProtKB 
canine protein database and the Matrisome Project database v.2 (Massachusetts Institute of 
Technology, Cambridge, Massachusetts) 56 and protein interaction network analysis was 
performed using STRING software v.10.5 (STRING Consortium 2017).  
For analysis of heavy isotope metabolic labelling, peptides for ECM proteins labelled 
with 13C lysine were initially identified using MASCOT v.2.6 (Matrix Science, London, UK). Raw 
data files were imported into Xcalibur v.3.0.63 (ThermoFisher Scientific) for analysis of 
extracted ion chromatograms and raw mass spectra. Heavy (H) and light (L) peaks were 
identified for each labelled peptide based on the observed m/z ratio and the scan number 
obtained from MASCOT. The area under each peak was recorded and relative isotope 
abundance (RIA) (the proportion of the total protein pool labelled with heavy isotope) was 
calculated as H/(L+H), indicating the level of new protein synthesis. The total protein pool was 
calculated as H+L, indicating the level of protein turnover. Further detail is given in Supporting 
Information. 
 
Statistical analysis 
Statistical analysis of stem cell characterisation data was performed using SigmaPlot 
(Systat Software Inc, California, USA)). Shapiro Wilk tests for normality were performed. For 
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normally distributed data parametric tests were used for pairwise comparisons. For data 
which was not normally distributed Log10 data transformations were performed before 
normality was confirmed and parametric tests used. For comparing two groups paired or 
independent Student’s t-tests were used, as appropriate. 
Statistical analysis of label-free protein quantification data was performed by PEAKS 
using an ANOVA. Proteins were considered to be significantly different between groups using 
a -10logP score of 15, a fold change of ≥ 2 and a quality score ≥ 0.2. For statistical analysis of 
metabolic labelling data a two-way ANOVA with repeated measures and a Holm-Sidak post-
hoc test was used. p-values of <0.05 were taken to be statistically significant for all data. 
 
 
Results 
 
LPCs display clonogenicity and stem cell marker expression  
Ligament-derived progenitor cells grew in heterogeneous dense colonies (Fig.1.A-C.) 
and showed a rounded and fibroblastic morphology upon initial plating (Fig.1.D.), with the 
rounded morphology lost with passaging. The gene expression of stem cell (OCT4, CD105, 
CD44, CD90 and CD73) and tenogenic (SCX, MKX and tenomodulin) markers was assessed by 
qRT-PCR (Fig.1.E.). Expression of Oct4 in LPCs was low, however CD marker expression was 
much higher. Tenogenic markers were expressed at much lower levels than CD markers. The 
expression of the haematopoietic markers CD34 and CD45 was also generally low (Fig.1.E.). 
 
LPCs display dual-lineage differentiation potential 
LPCs demonstrated signs of osteogenic, adipogenic and chondrogenic differentiation 
as assessed by alizarin red, oil red O and alcian blue staining respectively (Fig.2.A.). Gene 
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expression analysis of lineage specific genes showed a significant increase, between control 
and induced cultures, in the osteogenic marker RUNX2 (p=0.004), the adipogenic marker 
FABP4 (p=<0.0001) as well as an increase in the chondrogenic marker COL2, however this was 
not significant (Fig.2.B.). There was an increase in GAG content between control and induced 
samples from 1.6 (±1.0) µg to 2.1 (±1.9) µg, however this increase was not significant 
(Fig.2.C.).  
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Figure 1. Canine LPC morphology, clonogenicity and stem cell marker expression. Representative 
images of cell morphology and colony formation are shown. White bars = 100 μm, black bars = 1 cm 
(A). Colonies were counted (B) and measured (C) using ImageQuantTL software. Error bars shown 
represent SD. Representative images shown of LPCs after initial plating to emphasise differences in 
morphology. White bars = 100 μm (D). Gene expression analysis of stem cell markers in LPCs was 
performed using qRT-PCR (E). Values are shown on a logarithmic scale and normalised to GAPDH. 
n=9 biological replicates.  
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Figure 2. Dual-lineage differentiation potential of canine LPCs. Representative images are shown for histological 
staining of cells after induction of osteogenic, adipogenic and chondrogenic differentiation (positive) and for 
control samples (negative) (A). Cells subjected to osteogenic media were stained for calcium deposits using 
alizarin red (AR). Cells subjected to adipogenic media were stained for oil droplet formation using oil red O (ORO), 
and cell pellets exposed to chondrogenic media, for GAG formation using alcian blue (AB). Bar = 100 μm. Gene 
expression analysis of lineage specific markers was performed using qRT-PCR (B). Values are shown on a 
logarithmic scale and normalised to GAPDH. Error bars shown represent SD. 
a
p = 0.001, 
b
p = 0.001. Total GAG 
content of cell pellets with (positive) or without (negative) chondrogenic induction was measured (E). n=9 
biological replicates. 
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A variety of ECM proteins were identified in the LPC niche 
A total of 75 ECM related proteins were identified by PEAKS software and the 
Matrisome Project database as being produced by LPCs. The list of proteins is provided in 
Table S1. and the proportion of proteins belonging to each ECM category is shown in Figure 
3. The Matrisome Project categorised proteins into ECM collagens (10 proteins), ECM 
proteoglycans (6 proteins), ECM glycoproteins (14 proteins), ECM affiliated proteins (14 
proteins), ECM regulators (25 proteins) and secreted factors (6 proteins). A STRING protein 
interaction map showed strong interactions between collagens and some glycoproteins with 
weaker clusters forming for some regulatory and affiliated proteins (Fig.4). 
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ECM collagens
ECM 
proteoglycans
ECM 
glycoproteins
ECM affiliated 
proteins
ECM regulators
Secreted factors
Figure 3. Identification of ECM proteins produced by canine LPCs. ECM 
proteins produced by LPCs, as determined by PEAKS software, were divided 
into matrisomal protein categories according to the Matrisome Project 
database. 
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1 
Figure 4. Canine ligament ECM protein interactions. All ECM proteins produced by LPCs as 
determined by PEAKS software and the Matrisome Project were entered into STRING for visualisation 
of ECM protein interactions. 
Collagens 
Proteoglycans 
Glycoproteins 
Regulatory 
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Secreted/affiliated 
proteins 
Regulatory 
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18 
 
Metabolic labelling identified differences in dynamics between different ECM protein 
groups in LPCs 
ECM samples extracted from LPCs were analysed for new protein synthesis (heavy 
peptide content) and turnover (total peptide content) using LC-MS/MS after heavy isotope 
metabolic labelling. The data is presented as graphs demonstrating both total peptide 
quantity (total protein = heavy peptide + light peptide) and relative isotope abundance (RIA) 
which is the proportion of the total protein pool labelled with heavy isotope (calculated as 
heavy peptide/(light peptide + heavy peptide)) (Fig.5,6,7,S1).  
There was new synthesis of collagen type I alpha 1 and 2, collagen type III alpha 1 and 
collagen type VI alpha 1, 2 and 3. The general trend for new protein synthesis consisted of an 
initial increase in collagen synthesis over the first 24 hours, with a decrease seen at 48 hours. 
This is consistent with the protein turnover data which suggested an increase in total protein 
quantity over the first 24 hours and a decline at 48 hours (Fig.5). 
For proteoglycans new synthesis of decorin, lumican and tsukushi was observed and 
this generally increased over 48 hours. Consistent with this observation, total protein quantity 
also continued to increase over 48 hours (Fig.6). 
For glycoproteins there was new synthesis of transforming growth factor β1 (TGFβ1), 
tenascin C, fibronectin and elastin. Synthesis of new glycoproteins generally continued to 
increase over 48 hours. The total protein pool varied between glycoproteins, with some 
proteins demonstrating an increase in total protein quantity over time (such as tenascin C), 
consistent with the synthesis of new protein. In contrast, some proteins showed an initial 
increase in total protein quantity over 24 hours followed by a decrease at 48 hours (such as 
fibronectin and elastin), indicative of increased protein degradation between 24 and 48 hours 
(Fig.7). 
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For ECM regulators new synthesis of HtrA serine peptidases 1 and 3, cathepsins B and 
D and serpin peptidase inhibitors E2 and H1 was observed. Synthesis of new regulatory 
proteins generally continued to increase over 48 hours. The total protein content for ECM 
regulatory proteins increased over 24 hours and then started to decrease by 48 hours, 
indicative of increased protein degradation between 24 and 48 hours (Fig.S1).  
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Figure 5. Metabolic labelling of canine LPC collagens. Cells were labelled with 
13
C lysine for 4, 24 and 48 
hours before the ECM was harvested and LC-MS/MS performed. ECM proteins labelled with 
13
C lysine 
were identified using MASCOT and extracted ion chromatograms were analysed using Xcalibur. Heavy (H) 
and light (L) peaks were identified for each labelled peptide and the area under the peak recorded. Total 
peptide quantity (H+L) and relative isotope abundance (RIA) (H/(L+H)) are shown. Squares and circles 
represent different peptides. * = p<0.05, ** = p<0.01 and *** = p<0.001. 
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Figure 6. Metabolic labelling of canine LPC proteoglycans. Cells were labelled with 
13
C lysine for 4, 24 and 
48 hours before the ECM was harvested and LC-MS/MS performed. ECM proteins labelled with 
13
C lysine 
were identified using MASCOT and extracted ion chromatograms were analysed using Xcalibur. Heavy (H) 
and light (L) peaks were identified for each labelled peptide and the area under the peak recorded. Total 
peptide quantity (H+L) and relative isotope abundance (RIA) (H/(L+H)) are shown. Squares and circles 
represent different peptides. * = p<0.05, ** = p<0.01 and *** = p<0.001. 
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Figure 7. Metabolic labelling of canine LPC glycoproteins. Cells were labelled with 
13
C lysine for 4, 24 and 
48 hours before the ECM was harvested and LC-MS/MS performed. ECM proteins labelled with 
13
C lysine 
were identified using MASCOT and extracted ion chromatograms were analysed using Xcalibur. Heavy (H) 
and light (L) peaks were identified for each labelled peptide and the area under the peak recorded. Total 
peptide quantity (H+L) and relative isotope abundance (RIA) (H/(L+H)) are shown. Squares and circles 
represent different peptides. * = p<0.05, ** = p<0.01 and *** = p<0.001. 
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Discussion 
 
We have successfully isolated a progenitor cell population from the canine cranial 
cruciate ligament (CCL) that demonstrates many of the defined properties of stem cells. This 
cell population can form colonies, self-renew, express stem cell markers and can differentiate 
into osteogenic and adipogenic cell types; all traditional properties of stem cells (Fig.1-2). To 
date no other studies have isolated such cells from canine CCL and the identification of such 
a cell population may hold potential for stem cell therapy. Our findings are consistent with 
previous studies in humans, with LPCs isolated from human ACL demonstrating the same 
properties as the cells isolated in this study 18-20. Despite the stem cell properties 
demonstrated by the cell population selectively isolated in this study, it is likely that this is a 
heterogeneous population of cells, as clonal cell populations were not derived and different 
cell morphologies were observed upon initial plating. 
The stem cell population we have isolated could however hold therapeutic potential 
for treatment of ligament injuries. Previous studies have investigated the use of periodontal 
and medial collateral LPCs for repair of ligament with successful outcomes 22-24, 57, however 
no studies have yet investigated the use of LPCs from ACL or CCL to repair cruciate ligament 
injuries. LPCs may provide therapeutic benefit through differentiation into fibroblasts and 
ECM production or through immunomodulatory effects on the damaged tissue as 
demonstrated in mesenchymal stem cells 58-59. Identification of niche components which 
promote stem cell survival and function could provide potential therapeutic benefit by 
boosting the resident stem cells if introduced non-invasively to the damaged tissue in vivo.  
The present study has, for the first time, characterised the canine LPC niche, 
demonstrating the presence of collagens, proteoglycans, glycoproteins and ECM related 
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proteins (Fig.3-4). Although the growth of cells in 2D cell culture on fibronectin substrates 
may not mimic the natural environment of ligament cells, the cells grown on these conditions 
displayed stem cell characteristics, therefore, the niche produced by these cells is supportive 
of a stem/progenitor cell phenotype. This indicates that the described approach is an 
informative model, which is further confirmed by the consistency of our findings with 
previous literature looking at the proteome of whole canine CCL 35 and human ACL 60 tissue. 
Various collagens (types I, III, V, VI, XII), decorin, biglycan, lumican, osteoglycin, fibrinogen, 
fibromodulin, tenascin C, thrombospondin 1, TGFB1, vitronectin and elastin were identified 
in these studies 35, 60, consistent with our findings. No studies to date have investigated the 
ECM proteome of intra-articular ligament cells in 2D culture. However, several studies have 
demonstrated gene expression of ECM components by cultured human ACL and periodontal 
LPCs 20, 61-62, consistent with this study. One limitation of this study was the lack of analysis of 
ECM proteins secreted into the media. The role of some of the ECM proteins identified in this 
study in other stem cell niches has previously been demonstrated. For example, the role of 
tenascin C in the neural stem cell niche 26-27, fibronectin in the haematopoietic and embryonic 
stem cell niche 28-30, 63 and fibromodulin and biglycan in the tendon stem cell niche 31.  
The novel application of a metabolic labelling technique in this study enabled 
investigation of protein synthesis and turnover by LPCs (Fig.5-7). New protein synthesis was 
analysed by measuring the incorporation of heavy isotope into newly synthesised ECM 
proteins. This technique also provided information on protein turnover through analysis of 
total protein content. Synthesis and turnover of a number of ECM protein targets was 
observed, including collagens, proteoglycans, glycoproteins and ECM regulatory proteins. A 
general trend for collagens of an initial increase in new and total protein synthesis up to 24 
hours followed by a decrease between 24 and 48 hours was observed. At 24 hours a variable 
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RIA was observed for different collagens with as much as 93% of collagen type I alpha 1 being 
turned over in a 24 hour period and 46% of collagen type VI alpha 3. Previous studies have 
reported turnover rates of: 0.045%/h and 0.04%/h in human patellar tendon and ACL using 
metabolic labelling 64; a collagen half-life of 34-198 years in equine superficial digital flexor 
tendon by measuring aspartic racemization and collagen degradation 65; and a lack of 
turnover in human Achilles tendon demonstrated using the 14C bomb-pulse method 66. These 
turnover levels are considerably lower than our observations. This discrepancy may be due to 
the use of tissue in previous studies and the use of in vitro cultured cells in this study. 
Alternatively, newly-synthesised procollagen may be secreted from the cells but not 
incorporated into longer-lived collagen fibrils. The decline in total and labelled peptide seen 
at 48 hours is due to both reduced synthesis and increased degradation. The reduction in 
collagen synthesis may be due to changes in specific regulatory enzymes, such as the collagen 
chaperone Hsp47 (Serpin H1, Fig S1) and the increase in collagen degradation is most likely 
due to upregulation of collagen degrading enzymes, however only minor collagen 
degradation enzymes were identified. For proteoglycans there were a limited number of 
peptides which had been labelled with heavy isotope, therefore the conclusions we can draw 
for these proteins are with less confidence. The trend for proteoglycan turnover generally 
consisted of a continual increase in both total and heavy labelled peptide content. Previous 
reports have demonstrated high turnover of proteoglycans in tendon and ligament 67-71, 
consistent with this study. In our study, synthesis of new glycoproteins followed a similar 
pattern to proteoglycans with a continual increase over time, however total protein content 
was variable. This variability could reflect differences in regulation of these proteins and 
differences in function. Previous studies in equine tendon demonstrated a slow rate of 
turnover for non-collagenous proteins with a half-life of 2-3.5 years in tissue 65. In the present 
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study, synthesis of ECM regulatory proteins HtrA serine peptidase 1 and 2, cathepsin B and D 
and serpins E2 and H1 continually increased over time, whereas total protein content 
increased until 24 hours and then decreased between 24 and 48 hours. Little is known about 
the turnover of these ECM regulatory proteins, however due to their regulatory nature and 
the requirement for fast responsiveness to changing cellular demands it would be expected 
that their turnover would be high 72, as seen in this study. There are complex interactions 
between ECM core and regulatory proteins which may be reflected in their expression and 
turnover profiles. The high rate of turnover of ECM proteins seen in this study, when 
compared with other studies in tendon and ligament, is likely due to the intentional 
enrichment of stem/progenitor cells in culture and the requirement for faster proliferation 
and differentiation of stem/progenitor cells per se, with increased turnover of niche 
components providing an advantage 73. 
A limitation of this study is the lack of validated canine antibodies available for both 
stem cell markers and ECM proteins. Therefore, the gene expression of stem cell markers has 
been analysed rather than the phenotype. In addition, the lack of cross-reactivity of 
antibodies for canine proteins means we are unable to validate our mass spectrometry 
protein identifications. However, for the metabolic labelling data each peptide detected by 
MASCOT was manually verified in Xcalibur in order to calculate RIA therefore we have 
confidence in the proteins identified by MASCOT. Although Western blotting would have 
been useful to confirm protein identifications, this method is not appropriate for detecting 
alternations in protein dynamics and therefore would not have been a suitable method of 
validation for this novel aspect of the study. 
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Conclusions 
 
In conclusion, we have, for the first time, utilised a proteomics-based method to 
analyse the dynamics of newly synthesised ECM proteins in the extracellular niche of cultured 
cells. The study of protein dynamics is of vital importance, for comprehensive protein 
identification and to understand the function and regulation of proteins. It also enables a 
comparison of the dynamics of different proteins and highlights potential protein interactions 
and roles based on protein synthesis and degradation profiles. 
The identification of a stem cell population and investigation of the stem cell niche in 
canine CCL has not previously been reported. The novel cell population identified in this study 
may hold therapeutic potential for treatment of canine ligament injuries and the identified 
niche protein targets could be translated to therapies for human ligament damage. Future 
work should include further investigation of these novel protein targets and their role in the 
LPC niche as well as comparing the profile of stem cells and their niche in healthy and diseased 
ligament tissue. 
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